IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.17
-1.86 (-4.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close44.03
Open44.25
Bid41.50 x 1400
Ask44.10 x 900
Day's Range42.02 - 44.85
52 Week Range39.07 - 65.51
Volume1,065,730
Avg. Volume1,286,887
Market Cap5.293B
Beta3.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs
    Investor's Business Daily2 days ago

    Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs

    PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.

  • Don't Get Too Excited About PTC Therapeutics (Yet)
    Motley Fool2 days ago

    Don't Get Too Excited About PTC Therapeutics (Yet)

    PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.

  • Biogen and Ionis Crash on PTC Therapeutics’ Promising Data
    Market Realist3 days ago

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial

  • How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?
    Simply Wall St.3 days ago

    How Financially Strong Is Ionis Pharmaceuticals Inc (NASDAQ:IONS)?

    Mid-caps stocks, like Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a market capitalization of US$5.85B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...

  • Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle
    Motley Fool4 days ago

    Here's Why PTC Therapeutics Is Soaring While Biogen and Ionis Struggle

    Investors value a new round of data for PTC's spinal muscular atrophy drug.

  • Barrons.com11 days ago

    Biogen Buys $625 Million in Ionis Stock

    Biogen (BIIB) completed a pact to collaborate with Ionis Pharmaceuticals (IONS), and bought 11.5 million Ionis shares for $625 million, paying $54.34 each. Biogen also invested $375 million as an upfront payment to Ionis to "jointly discover and develop novel antisense drugs for a broad range of neurological diseases," as stated in a press release. In total, Biogen laid out $1 billion in cash.

  • 3 Top Biotech Stocks to Buy in June
    Motley Fool18 days ago

    3 Top Biotech Stocks to Buy in June

    The cure for your portfolio's ills might be found in these three mid-cap biotech stocks.

  • Better Buy: Biogen Inc. vs. Celgene
    Motley Fool19 days ago

    Better Buy: Biogen Inc. vs. Celgene

    Which of these beaten-down biotech stocks wins in a head-to-head match-up?

  • The Upside Potential in Editas Medicine Stock
    Market Realist24 days ago

    The Upside Potential in Editas Medicine Stock

    Editas has key collaboration agreements with Juno Therapeutics and Allergan Pharmaceuticals. Of the nine analysts covering Editas Medicine in May, five have given the stock “buy” or higher ratings, three have given it “hold” ratings, and one has given it a “strong sell” rating. The mean rating for the stock is 2.67, and its target price is $45.2, implying an upside potential of 23.4% over its closing price of $36.63 on May 24.

  • How Clovis Oncology’s Cash Flow and Valuation Compare
    Market Realist25 days ago

    How Clovis Oncology’s Cash Flow and Valuation Compare

    In the first quarter, Clovis Oncology’s (CLVS) operating expenses rose YoY (year-over-year) to $100.6 million from $80.4 million, due to a larger net loss and inventories rising. Clovis’s investments fell YoY to $9.8 million from $86.6 million due to the company buying $133 million in available-for-sale securities and selling $50 million in securities in 2017. In the first quarter of this year, Clovis sold $10 million in available-for-sale securities and purchased $217,000 in property and equipment. Clovis generated $226.9 million from financing activities in the first quarter of 2017.

  • What’s Clovis Oncology’s Return Potential?
    Market Realist25 days ago

    What’s Clovis Oncology’s Return Potential?

    Clovis Oncology (CLVS) is a biopharmaceutical company with a focus on acquiring, developing, and commercializing anti-cancer agents. Clovis’s Rubraca (rucaparib), launched in the United States in December 2016, is approved for treating adult patients with deleterious BRCA1-mutation epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received two or more chemotherapies. Of the nine analysts covering Clovis Oncology, seven have recommended “buy” or a higher rating, while two have recommended “hold.” Clovis’s target price of $79.57 implies a 67.4% upside based on the stock’s May 24 closing price of $47.52.

  • What Analysts Think about Ionis
    Market Realist28 days ago

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million. Analysts expect Ionis’s top line to rise ~30.2% to ~$135.7 million in the second quarter. The chart below shows analysts’ recommendations for Ionis stock over the last year.

  • How Ionis’s Spinraza Did in Q1
    Market Realist28 days ago

    How Ionis’s Spinraza Did in Q1

    Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is an FDA-approved drug designed for the treatment of spinal muscular atrophy, a type of severe motor-neuron disease in pediatric patients and adults. Biogen (BIIB), which has held the worldwide development and commercialization rights for Spinraza since January 2012, forwards royalties to Ionis.

  • Analyzing Ionis’s Q1 Revenue Streams
    Market Realist28 days ago

    Analyzing Ionis’s Q1 Revenue Streams

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.

  • Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
    Market Realist28 days ago

    Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?

    How Is Alnylam Pharmaceuticals Positioned in 2018? Since the beginning of 2018, the stock price of Alnylam Pharmaceuticals has dropped from $130 levels to $100 as of May 21. Overall, Alnylam Pharmaceuticals has fallen 24%.

  • What Drove Ionis’s Revenue in Q1
    Market Realist29 days ago

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.

  • Ionis Pharmaceuticals’ Valuation on May 23
    Market Realist29 days ago

    Ionis Pharmaceuticals’ Valuation on May 23

    Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases. The chart below compares Ionis’s revenue and EPS since Q1 2017. In the first quarter, Ionis’s revenue rose ~24.7% year-over-year to $144.4 million from $115.8 million.

  • Analyst Views on the Upside Potential of Alnylam Pharmaceuticals
    Market Realist29 days ago

    Analyst Views on the Upside Potential of Alnylam Pharmaceuticals

    How Is Alnylam Pharmaceuticals Positioned in 2018? Alnylam Pharmaceuticals (ALNY) is a global biopharmaceutical company focused on developing RNA interference-based novel therapeutics. Alnylam is harnessing this pathway to develop a new class of innovative medicines called RNAi therapeutics.

  • Benzingalast month

    Uniqure Notches Bullish Initiation On Gene Therapy Prospects

    Uniqure NV (NASDAQ: QURE ) has managed to win the seal of approval from Wells Fargo Securities due to its gene therapy pipeline candidates that target multiple diseases.  The Analyst Analyst Jim Birchenough ...

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Foollast month

    3 Top Biotech Stocks to Buy Right Now

    Want to invest in this promising industry but don't know where to start? Here are three stocks that can get the ball rolling.

  • Why Akcea Therapeutics Rocketed Higher Today
    Motley Foollast month

    Why Akcea Therapeutics Rocketed Higher Today

    An FDA advisory committee endorsed the biotech's lead drug, but an approval is far from a slam dunk.

  • Market Exclusivelast month

    Akcea and Ionis Just Got A Major Boost

    We are closing in on the end of another week in the biotechnology space just as was the case last week, we’ve seen plenty of movement in the sector on the back of a number of fresh releases. Here is a look at the most pertinent and a description of what it means for the […] The post Akcea and Ionis Just Got A Major Boost appeared first on Market Exclusive.

  • Ionis Pharmaceuticals Prepares for Launch
    Motley Foollast month

    Ionis Pharmaceuticals Prepares for Launch

    The biotech has the potential for two FDA approvals this year.

  • See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of IONS earnings conference call or presentation 4-May-18 3:30pm GMT

    Q1 2018 Ionis Pharmaceuticals Inc Earnings Call